News
-
-
-
COMMUNIQUÉ DE PRESSE
Cyprumed Enters License and Option Agreement with MSD for the Development of Oral Peptide Therapeutics
Cyprumed and MSD sign a Non-Exclusive License and Option Agreement for the Development of Oral Peptide Therapeutics, potentially unlocking new opportunities in peptide therapeutics